IntelGenx Technologies Corp. (IGX) Analysts See $-0.02 EPS on May, 10

May 3, 2018 - By Heather Owens

IntelGenx Technologies Corp. (CVE:IGX) Corporate Logo

IntelGenx Technologies Corp. (CVE:IGX) is anticipated to publish earnings on May, 10., Zacks reports. Analysts predict 100.00 % diference or $-0.02 from the $-0.01 EPS from 2017. Analysts at Wall Street see IntelGenx Technologies Corp.’s -33.33 % EPS growth compared to $-0.03 EPS for last quarter. IGX hit $0.87 during the last trading session after $0.05 change.IntelGenx Technologies Corp. has volume of 3,325 shares. Since May 3, 2017 IGX has 0.00% and is . IGX underperformed by 11.55% the S&P500.

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market.The firm is valued at $62.96 million. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines.Last it reported negative earnings. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: